A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Safety and Efficacy of 3 Dose Levels of AV-1 in Healthy Adults Challenged With a Controlled Human Infection Strain of DENV-3
Latest Information Update: 02 Jun 2025
At a glance
- Drugs AV-1 AbViro LLC (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors AbViro
Most Recent Events
- 28 May 2025 Planned End Date changed from 7 Oct 2025 to 28 Nov 2025.
- 28 May 2025 Planned primary completion date changed from 7 Oct 2025 to 28 Nov 2025.
- 04 Feb 2025 New trial record